{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:19:37Z","timestamp":1792279177937,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005609","name":"University of Turku","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005609","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10620-025-08876-5","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:15:31Z","timestamp":1739459731000},"page":"1457-1466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-6764","authenticated-orcid":false,"given":"Jaakko","family":"Rautakorpi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5176-9709","authenticated-orcid":false,"given":"Sara","family":"Kolehmainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7278-6511","authenticated-orcid":false,"given":"Eliisa","family":"L\u00f6yttyniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-8612","authenticated-orcid":false,"given":"Clas-G\u00f6ran af","family":"Bj\u00f6rkesten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2194-0424","authenticated-orcid":false,"given":"Perttu","family":"Arkkila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8069-5273","authenticated-orcid":false,"given":"Taina","family":"Sipponen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-9240","authenticated-orcid":false,"given":"Kimmo","family":"Salminen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"8876_CR1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB et al. Ulcerative colitis. The Lancet 2017;389:1756\u20131770. https:\/\/doi.org\/10.1016\/S0140-6736(16)32126-2.","journal-title":"The Lancet"},{"key":"8876_CR2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn\u2019s disease. The Lancet 2017;389:1741\u20131755. https:\/\/doi.org\/10.1016\/S0140-6736(16)31711-1.","journal-title":"The Lancet"},{"key":"8876_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/2050640615590302","volume":"3","author":"J C\u00f4t\u00e9-Daigneault","year":"2015","unstructured":"C\u00f4t\u00e9-Daigneault J, Bouin M, Lahaie R et al. Biologics in inflammatory bowel disease: what are the data? United European Gastroenterol J 2015;3:419\u2013428. https:\/\/doi.org\/10.1177\/2050640615590302.","journal-title":"United European Gastroenterol J"},{"key":"8876_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"2020","author":"J Torres","year":"2019","unstructured":"Torres J, Bonovas S, Doherty G et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis 2019;2020:4\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180.","journal-title":"J Crohns Colitis"},{"key":"8876_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ECCO-JCC\/JJAB178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 2022;16:2\u201317. https:\/\/doi.org\/10.1093\/ECCO-JCC\/JJAB178.","journal-title":"J Crohns Colitis"},{"key":"8876_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/CROCOL\/OTAA093","author":"S Bhat","year":"2021","unstructured":"Bhat S, Qazi T. Switching from infliximab to biosimilar in inflammatory bowel disease: a review of existing literature and best practices. Crohns Colitis 360. 2021. https:\/\/doi.org\/10.1093\/CROCOL\/OTAA093.","journal-title":"Crohns Colitis 360"},{"key":"8876_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/NRGASTRO.2016.155","volume":"14","author":"S Danese","year":"2016","unstructured":"Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nature Reviews Gastroenterology & Hepatology 2016;14:22\u201331. https:\/\/doi.org\/10.1038\/NRGASTRO.2016.155.","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"8876_CR8","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1097\/MIB.0B013E3182A19268","volume":"19","author":"A Buisson","year":"2013","unstructured":"Buisson A, Seigne AL, D\u2019Huart MC et al. The extra burden of infliximab infusions in inflammatory Bowel disease. Inflamm Bowel Dis 2013;19:2464\u20132467. https:\/\/doi.org\/10.1097\/MIB.0B013E3182A19268.","journal-title":"Inflamm Bowel Dis"},{"key":"8876_CR9","unstructured":"EMA (2020) Remsima: EPAR\u2014product information."},{"key":"8876_CR10","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/J.GASTRO.2021.02.068","volume":"160","author":"S Schreiber","year":"2021","unstructured":"Schreiber S, Ben-Horin S, Leszczyszyn J et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory Bowel disease. Gastroenterology 2021;160:2340\u20132353. https:\/\/doi.org\/10.1053\/J.GASTRO.2021.02.068.","journal-title":"Gastroenterology"},{"key":"8876_CR11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/ECCO-JCC\/JJAC053","volume":"16","author":"PJ Smith","year":"2022","unstructured":"Smith PJ, Critchley L, Storey D et al. Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicentre Cohort study. J Crohns Colitis 2022;16:1436\u20131446. https:\/\/doi.org\/10.1093\/ECCO-JCC\/JJAC053.","journal-title":"J Crohns Colitis"},{"key":"8876_CR12","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","volume":"21","author":"A Buisson","year":"2023","unstructured":"Buisson A, Nachury M, Reymond M et al. Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory Bowel diseases: the REMSWITCH study. Clinical Gastroenterology and Hepatology 2023;21:2338\u20132346.e3. https:\/\/doi.org\/10.1016\/j.cgh.2022.08.011.","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"8876_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/IBD\/IZAD094","volume":"30","author":"SN Hong","year":"2024","unstructured":"Hong SN, Song JH, Kim SJ et al. One-year clinical outcomes of subcutaneous infliximab maintenance therapy compared with intravenous infliximab maintenance therapy in patients with inflammatory Bowel disease: a prospective Cohort study. Inflamm Bowel Dis 2024;30:517\u2013528. https:\/\/doi.org\/10.1093\/IBD\/IZAD094.","journal-title":"Inflamm Bowel Dis"},{"key":"8876_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","volume":"315","author":"RF Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM. A simple index of Crohn\u2019s-disease activity. The Lancet 1980;315:514. https:\/\/doi.org\/10.1016\/S0140-6736(80)92767-1.","journal-title":"The Lancet"},{"key":"8876_CR15","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ibd.20520","volume":"14","author":"JD Lewis","year":"2008","unstructured":"Lewis JD, Chuai S, Nessel L et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008;14:1660\u20131666. https:\/\/doi.org\/10.1002\/ibd.20520.","journal-title":"Inflamm Bowel Dis"},{"key":"8876_CR16","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s10620-017-4770-0","volume":"62","author":"AM Puolanne","year":"2017","unstructured":"Puolanne AM, Kolho KL, Alfthan H et al. Rapid fecal calprotectin test and symptom index in monitoring the disease activity in colonic inflammatory Bowel disease. Dig Dis Sci 2017;62:3123\u20133130. https:\/\/doi.org\/10.1007\/s10620-017-4770-0.","journal-title":"Dig Dis Sci"},{"key":"8876_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc 2004;60:505\u2013512. https:\/\/doi.org\/10.1016\/S0016-5107(04)01878-4.","journal-title":"Gastrointest Endosc"},{"key":"8876_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/CROCOL\/OTAB007","author":"AN Naegeli","year":"2021","unstructured":"Naegeli AN, Hunter T, Dong Y et al. Full, partial, and modified permutations of the Mayo score: characterizing clinical and patient-reported outcomes in ulcerative colitis patients. Crohns Colitis 360. 2021. https:\/\/doi.org\/10.1093\/CROCOL\/OTAB007.","journal-title":"Crohns Colitis 360"},{"key":"8876_CR19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/J.CGH.2015.06.001","volume":"14","author":"L Peyrin-Biroulet","year":"2016","unstructured":"Peyrin-Biroulet L, Pan\u00e9s J, Sandborn WJ et al. Defining disease severity in inflammatory Bowel diseases: current and future directions. Clin Gastroenterol Hepatol 2016;14:348\u2013354.e17. https:\/\/doi.org\/10.1016\/J.CGH.2015.06.001.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8876_CR20","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.3390\/BIOMEDICINES10092130","volume":"10","author":"JM Huguet","year":"2022","unstructured":"Huguet JM, Garc\u00eda-Lorenzo V, Mart\u00ed L et al. Subcutaneous infliximab [CT-P13], a true biologic 2.0: real clinical practice multicenter study. Biomedicines 2022;10:2130. https:\/\/doi.org\/10.3390\/BIOMEDICINES10092130.","journal-title":"Biomedicines"},{"key":"8876_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/IBD\/IZAB099","volume":"28","author":"J Hanzel","year":"2022","unstructured":"Hanzel J, Jansen JM, Ter Steege RWF et al. Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory Bowel disease: a prospective multicenter Cohort study. Inflamm Bowel Dis 2022;28:495\u2013501. https:\/\/doi.org\/10.1093\/IBD\/IZAB099.","journal-title":"Inflamm Bowel Dis"},{"key":"8876_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/APT.17822","volume":"59","author":"A Buisson","year":"2024","unstructured":"Buisson A, Nachury M, Bazoge M et al. Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: the REMSWITCH-LT study. Aliment Pharmacol Ther 2024;59:526\u2013534. https:\/\/doi.org\/10.1111\/APT.17822.","journal-title":"Aliment Pharmacol Ther"},{"key":"8876_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/00365521.2023.2285229","volume":"59","author":"J Harno-Tasihin","year":"2024","unstructured":"Harno-Tasihin J, Siregar L, Paajanen M et al. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses. Scand J Gastroenterol 2024;59:280\u2013287. https:\/\/doi.org\/10.1080\/00365521.2023.2285229.","journal-title":"Scand J Gastroenterol"},{"key":"8876_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/IBD.20312","volume":"14","author":"T Sipponen","year":"2008","unstructured":"Sipponen T, Savilahti E, Kolho KL et al. Crohn\u2019s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn\u2019s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40\u201346. https:\/\/doi.org\/10.1002\/IBD.20312.","journal-title":"Inflamm Bowel Dis"},{"key":"8876_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000201441","volume":"58","author":"AG R\u00f8seth","year":"1997","unstructured":"R\u00f8seth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176\u2013180. https:\/\/doi.org\/10.1159\/000201441.","journal-title":"Digestion"},{"key":"8876_CR26","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/PPA.S303279","volume":"15","author":"PM Overton","year":"2021","unstructured":"Overton PM, Shalet N, Somers F, Allen JA. Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adherence 2021;15:811. https:\/\/doi.org\/10.2147\/PPA.S303279.","journal-title":"Patient Prefer Adherence"},{"key":"8876_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/J.GASTRO.2024.05.006","volume":"167","author":"SB Hanauer","year":"2024","unstructured":"Hanauer SB, Sands BE, Schreiber S et al. Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY). Gastroenterology 2024;167:919\u2013933. https:\/\/doi.org\/10.1053\/J.GASTRO.2024.05.006.","journal-title":"Gastroenterology"},{"key":"8876_CR28","doi-asserted-by":"publisher","first-page":"6173","DOI":"10.3390\/JCM11206173","volume":"11","author":"RD Little","year":"2022","unstructured":"Little RD, Ward MG, Wright E et al. (2022) Therapeutic drug monitoring of subcutaneous infliximab in inflammatory bowel disease\u2014understanding pharmacokinetics and exposure response relationships in a new era of subcutaneous biologics. Journal of Clinical Medicine 2022;11:6173. https:\/\/doi.org\/10.3390\/JCM11206173.","journal-title":"Journal of Clinical Medicine"},{"key":"8876_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/IBD\/IZAE231","author":"R Porth","year":"2024","unstructured":"Porth R, Deyhim T, Geeganage G et al. proactive therapeutic drug monitoring of Ustekinumab is associated with increased drug persistence in patients with inflammatory Bowel disease. Inflamm Bowel Dis. 2024. https:\/\/doi.org\/10.1093\/IBD\/IZAE231.","journal-title":"Inflamm Bowel Dis"},{"key":"8876_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/S10620-023-08252-1\/FIGURES\/4","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Bossuyt P, Bettenworth D et al. Comparative efficacy of subcutaneous and intravenous infliximab and vedolizumab for maintenance treatment of TNF-naive adult patients with inflammatory bowel disease: a systematic literature review and network meta-analysis. Dig Dis Sci. 2024. https:\/\/doi.org\/10.1007\/S10620-023-08252-1\/FIGURES\/4.","journal-title":"Dig Dis Sci"},{"key":"8876_CR31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/ECCO-JCC\/JJAD188","volume":"18","author":"X Roblin","year":"2024","unstructured":"Roblin X, Nancey S, Papamichael K et al. Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease. J Crohns Colitis 2024;18:679\u2013685. https:\/\/doi.org\/10.1093\/ECCO-JCC\/JJAD188.","journal-title":"J Crohns Colitis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08876-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-08876-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08876-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T01:49:23Z","timestamp":1743904163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-08876-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["8876"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-08876-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.R. has received support from Abbvie, Pfizer, and Takeda for meeting attendance and travel expenses and has participated in planning educational meetings for Abbvie. C.G.B. has received speaker and consultant fees from Abbvie, BMS, Galapagos, Johnson & Johnson, Lilly, Pfizer, Takeda, and Tillotts. P.A. has participated in planning educational meetings for Takeda, is a shareholder in Orion Pharma, and has received lecture fees from Celltrion. K.S. has received speaker and consultant fees from Abbvie, BMS, Janssen, Pfizer, Takeda, and Tillotts Pharma. T.S. has received speaker fees from Abbvie, Celltrion, Johnson & Johnson, Lilly, and Takeda, as well as consultation fees from Abbvie, BMS, Johnson & Johnson, Pfizer, and Takeda and a research grant from Johnson & Johnson. S.K. and E.L. have no conflicts of interest to declare. J.R. has received grant from the Mary and Georg C. Ehrnrooth Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}